Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | IDH inhibitors and the evolving AML treatment paradigm

Stéphane de Botton • 5 Jun 2022
ASCO 2022
Acute Myeloid Leukemia Leukemia

Stéphane de Botton, MD, PhD, Gustave Roussy Institute, Paris, France, reflects on the evolving treatment paradigm of acute myeloid leukemia (AML), highlighting the role of IDH inhibitors in various populations of AML. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Stéphane de Botton

3:52
A Phase II study evaluating the safety and efficacy of olutasidenib in patients with R/R mIDH1 AML
Stéphane de Botton • 28 Nov 2022
6:53
The efficacy and toxicity of reduced venetoclax exposure in patients with treatment-naïve AML
Stéphane de Botton • 28 Nov 2022
2:15
Treatment strategies for patients with AML who possess a FLT3 mutation
Stéphane de Botton • 28 Nov 2022
4:19
Molecular characterization of patients in AGILE: azacitidine + ivosidenib or placebo in IDH1m AML
Stéphane de Botton • 28 Nov 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals